Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gallbladder01:17

Gallbladder

3.4K
The gallbladder is a small, pear-shaped organ that plays a crucial role in our digestive system. Measuring about 10 cm in length, it is comparable in size to a kiwi fruit and is located in a hollow area on the lower surface of the liver. The gallbladder's primary function is to store and concentrate bile, a fluid produced by the liver that aids in digestion.
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins...
3.4K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

950
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
950
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early clinical experience with ⁶⁸Ga-Trivehexin PET/CT in parathyroid adenomas: a proof-of- concept imaging study.

Annals of nuclear medicine·2026
Same author

Investigating the relationship between thyroid replacement therapy goals status and quality of life in patients with primary hypothyroidism.

Endocrine·2026
Same author

Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.

Obesity facts·2026
Same author

Prevalence and Species Distribution of House Dust Mites in Household Dust Samples from Homes of Individuals with Allergic Complaints in Ordu, Turkey.

Journal of visualized experiments : JoVE·2026
Same author

Ultrasound-Guided Radiofrequency Ablation for the Treatment of Primary Hyperparathyroidism in Elderly Patients.

Clinical endocrinology·2026
Same author

Nailfold Capillary Changes in Primary Hyperparathyroidism.

Clinical endocrinology·2026

Related Experiment Video

Updated: Apr 16, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.9K

Liraglutide-related cholelithiasis.

Hakan Korkmaz1, Mustafa Araz2, Samet Alkan3

  • 1Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey. drhkorkmaz@yahoo.com.tr.

Aging Clinical and Experimental Research
|March 2, 2015
PubMed
Summary

This case report details the first instance of liraglutide-induced cholelithiasis (gallstones) in a type 2 diabetes patient. Ursodeoxycholic acid treatment led to gallstone regression, suggesting a potential non-surgical option.

Keywords:
CholelithiasisLiraglutideUrsodeoxycholic acid

More Related Videos

The Role of Indocyanine Green Fluorescence in Complex Laparoscopic Cholecystectomy Navigation
03:27

The Role of Indocyanine Green Fluorescence in Complex Laparoscopic Cholecystectomy Navigation

Published on: January 31, 2025

1.6K
Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery
04:03

Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery

Published on: March 28, 2025

683

Related Experiment Videos

Last Updated: Apr 16, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.9K
The Role of Indocyanine Green Fluorescence in Complex Laparoscopic Cholecystectomy Navigation
03:27

The Role of Indocyanine Green Fluorescence in Complex Laparoscopic Cholecystectomy Navigation

Published on: January 31, 2025

1.6K
Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery
04:03

Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery

Published on: March 28, 2025

683

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Pharmacology

Background:

  • Liraglutide, a glucagon-like peptide-1 analog, is an incretin-based therapy for diabetes mellitus.
  • Common side effects include nausea, vomiting, nasopharyngitis, and pancreatitis.
  • Liraglutide-associated cholelithiasis has not been previously documented.

Observation:

  • A 75-year-old female with a 10-year history of type 2 diabetes presented with acute abdominal pain.
  • Diagnosis included acute cholecystitis and cholelithiasis after 6 months of liraglutide treatment.
  • Liraglutide was discontinued, and ursodeoxycholic acid (UDCA) was initiated for gallstone management.

Findings:

  • The patient experienced complete relief of abdominal pain.
  • Hepatobiliary ultrasonography at six months showed complete regression of cholelithiasis.
  • This represents the first reported case of liraglutide-dependent cholelithiasis.

Implications:

  • Elderly diabetic patients initiating liraglutide require close monitoring for gallstone formation.
  • Ursodeoxycholic acid may serve as an effective alternative to surgery for liraglutide-related cholelithiasis.
  • Further research is warranted to elucidate the mechanism of liraglutide-induced gallstone formation.